X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with ALEMBIC LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ALEMBIC LTD VENUS REMEDIES/
ALEMBIC LTD
 
P/E (TTM) x -821.4 75.1 - View Chart
P/BV x 0.2 2.8 8.6% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   ALEMBIC LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ALEMBIC LTD
Mar-16
VENUS REMEDIES/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs21853 412.9%   
Low Rs8229 280.2%   
Sales per share (Unadj.) Rs365.64.7 7,746.7%  
Earnings per share (Unadj.) Rs1.58.8 16.9%  
Cash flow per share (Unadj.) Rs37.99.0 421.2%  
Dividends per share (Unadj.) Rs00.15 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs382.527.7 1,379.7%  
Shares outstanding (eoy) m11.44267.03 4.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.48.7 4.7%   
Avg P/E ratio x101.04.7 2,158.1%  
P/CF ratio (eoy) x4.04.6 86.8%  
Price / Book Value ratio x0.41.5 26.5%  
Dividend payout %01.7 0.0%   
Avg Mkt Cap Rs m1,71710,962 15.7%   
No. of employees `0001.0NA-   
Total wages/salary Rs m324238 136.3%   
Avg. sales/employee Rs Th4,100.7NM-  
Avg. wages/employee Rs Th318.0NM-  
Avg. net profit/employee Rs Th16.7NM-  
INCOME DATA
Net Sales Rs m4,1831,260 331.9%  
Other income Rs m20264 7.6%   
Total revenues Rs m4,2031,524 275.8%   
Gross profit Rs m81283 980.2%  
Depreciation Rs m41761 678.8%   
Interest Rs m3800 126,600.0%   
Profit before tax Rs m35285 12.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m0-32 0.0%   
Tax Rs m186 296.7%   
Profit after tax Rs m172,343 0.7%  
Gross profit margin %19.46.6 295.3%  
Effective tax rate %51.62.1 2,408.4%   
Net profit margin %0.4185.9 0.2%  
BALANCE SHEET DATA
Current assets Rs m2,7711,689 164.1%   
Current liabilities Rs m1,931486 397.2%   
Net working cap to sales %20.195.4 21.0%  
Current ratio x1.43.5 41.3%  
Inventory Days Days125217 57.6%  
Debtors Days Days5481 66.3%  
Net fixed assets Rs m5,3281,624 328.1%   
Share capital Rs m114534 21.4%   
"Free" reserves Rs m4,1775,960 70.1%   
Net worth Rs m4,3767,404 59.1%   
Long term debt Rs m1,911104 1,831.7%   
Total assets Rs m8,4288,010 105.2%  
Interest coverage x1.1950.7 0.1%   
Debt to equity ratio x0.40 3,099.0%  
Sales to assets ratio x0.50.2 315.4%   
Return on assets %4.729.3 16.1%  
Return on equity %0.431.6 1.2%  
Return on capital %6.631.3 21.1%  
Exports to sales %02.9 0.0%   
Imports to sales %20.528.9 71.1%   
Exports (fob) Rs mNA37 0.0%   
Imports (cif) Rs m858364 236.0%   
Fx inflow Rs m037 0.0%   
Fx outflow Rs m858365 235.2%   
Net fx Rs m-858-328 261.8%   
CASH FLOW
From Operations Rs m469346 135.6%  
From Investments Rs m29-48 -61.3%  
From Financial Activity Rs m-464-301 154.0%  
Net Cashflow Rs m35-3 -1,150.0%  

Share Holding

Indian Promoters % 32.9 64.0 51.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.2 90.0%  
FIIs % 0.6 9.7 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 26.1 254.4%  
Shareholders   20,121 54,701 36.8%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   GLENMARK PHARMA  FULFORD INDIA  WYETH LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 23, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS